News
Dr Kunz on Time to Response With Lutetium Lu 177 Dotatate in GEP-NETs
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center, discusses findings from a subanalysis of the phase 3 NETTER-2 study (NCT03972488) investigating frontline lutetium Lu 177 dotatate (Lutathera) in patients with advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Source: OncLive